STOCK TITAN

Merck & Co - MRK STOCK NEWS

Welcome to our dedicated page for Merck & Co news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co stock.

Merck & Co. (NYSE: MRK) is a global pharmaceutical leader with a 350-year legacy of medical innovation. This news hub provides investors and healthcare professionals with direct access to official announcements, financial disclosures, and research developments shaping the company's trajectory.

Track MRK's latest regulatory milestones, clinical trial results, and strategic partnerships through verified press releases and curated analysis. Our repository includes earnings call transcripts, FDA approval updates, and global health initiatives—all organized for efficient research and due diligence.

Key updates on therapeutic advancements in oncology, vaccines, and infectious diseases are maintained alongside financial performance data. Bookmark this page for real-time access to Merck's corporate communications and market-moving developments in the pharmaceutical sector.

Rhea-AI Summary
Merck announces positive results from the Phase 3 KEYNOTE-811 trial evaluating KEYTRUDA in combination with trastuzumab and chemotherapy for the treatment of HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
none
-
Rhea-AI Summary
Merck announces positive results from the Phase 3 KEYNOTE-671 trial evaluating KEYTRUDA as a perioperative treatment regimen for resectable non-small cell lung cancer (NSCLC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
none
-
Rhea-AI Summary
Daiichi Sankyo and Merck have entered into a global development and commercialization agreement for three antibody drug conjugate (ADC) candidates. Merck will pay Daiichi Sankyo a total potential consideration of up to $22 billion. The ADC candidates are in various stages of clinical development for the treatment of multiple solid tumors. Financial terms of the agreement include upfront payments and sales milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
none
Rhea-AI Summary
Merck's PREVYMIS receives positive recommendation from CHMP for the prevention of CMV disease in kidney transplant recipients and extended dosing for HSCT recipients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags
none
-
Rhea-AI Summary
Merck's anti-PD-1 therapy, KEYTRUDA, has received FDA approval for the treatment of resectable non-small cell lung cancer (NSCLC) in combination with chemotherapy. The approval was based on positive results from a Phase 3 trial, showing statistically significant improvements in event-free survival and overall survival compared to placebo and chemotherapy. This marks the sixth indication for KEYTRUDA in NSCLC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
none
-
Rhea-AI Summary
KEYTRUDA demonstrates significant improvement in overall survival for lung cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
Rhea-AI Summary
Merck is collaborating to address antimicrobial resistance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
none
Merck & Co

NYSE:MRK

MRK Rankings

MRK Stock Data

199.22B
2.51B
0.07%
80.45%
1.62%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
KENILWORTH